Cohance Lifesciences Limited — Financials & Forensics
Sector: Healthcare · NSE: COHANCE · BSE: 543064 · ISIN: INE03QK01018
11 Sep 2026
Add COHANCE to your watchlist — all of this, automated.
Sign in with GoogleAnnual P&L snapshot
| Line item | FY21 | FY22 | FY23 | FY24 | FY26 |
|---|---|---|---|---|---|
| Revenue from operations | ₹1,010 Cr | ₹1,320 Cr | ₹1,340 Cr | ₹1,051 Cr | ₹2,269 Cr |
| EBITDA | ₹440 Cr | ₹579 Cr | ₹567 Cr | ₹406 Cr | ₹427 Cr |
| EBITDA margin | 43.6% | 43.9% | 42.3% | 38.6% | 18.8% |
| Profit after tax | ₹362 Cr | ₹454 Cr | ₹411 Cr | ₹300 Cr | ₹150 Cr |
Deeper analysis
Recent filings by Cohance Lifesciences Limited
-
Analysts/Institutional Investor Meet/Con. Call Updates
05 Aug 2026 · General Update
-
Completion of USFDA Inspection
05 Aug 2026 · Regulatory Compliance
-
Outcome of the Board Meeting
05 Aug 2026 · Board Meeting
Never miss a filing again
About Cohance Lifesciences Limited on Indian Stock Alerts
Indian Stock Alerts tracks Cohance Lifesciences Limited's SEBI / exchange filings in real time. Every quarterly result, audited annual report, shareholding pattern update, insider trade and corporate announcement is automatically parsed and surfaced as a structured data point — with a link back to the underlying filing.
Data points refreshed daily include closing price, 1Y change, market cap, P/E, ROE, dividend yield, RPT volume, audit / governance / accrual flags. Quarterly results numbers refresh within minutes of the company filing them with BSE / NSE.